HORIZON-PFT
Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly
Patient / Population Intervention / Exposure Comparison Outcome
In 7,765 postmenopausal women with osteoporosis, annual intravenous zoledronic acid 5 mg reduced new vertebral and hip fractures compared with placebo.
N
7,765
Design
Double-blind RCT, 3 yr
Endpoint
New morphometric vertebral fracture
Relevance
2
ResultVertebral fracture RR 0.30 (p<0.001); hip fracture HR 0.59 (−41 %; p=0.002).
Black DM, et al. N Engl J Med. 2007;356(18):1809-1822. 10.1056/NEJMoa067312
Discussion & critique
Established annual intravenous bisphosphonate dosing — the option for patients intolerant of oral therapy or with adherence concerns.